Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01272635
Other study ID # AsthmaNet 002
Secondary ID 1U10HL098115
Status Completed
Phase Phase 3
First received January 7, 2011
Last updated January 9, 2015
Start date March 2011
Est. completion date January 2015

Study information

Verified date January 2015
Source Milton S. Hershey Medical Center
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This protocol is comprised of two separate, but linked, clinical trials for treating preschool-aged children with recurrent severe episodes of wheezing. The first study (APRIL) will try to prevent wheezing illness from developing using azithromycin. If a wheezing illness does occur, the second trial (OCELOT) will try to decrease the severity of symptoms using oral corticosteroids.


Description:

Preschool aged children often have severe bouts of coughing and/or wheezing that lead to visits to the doctor's office, urgent care, emergency room and often hospitalization. APRIL-OCELOT is a randomized, double-blind, placebo controlled study in 600 preschool children with a history of significant wheezing episodes in the year prior to enrollment. All children enter the APRIL portion of the study, which will compare azithromycin to placebo, given for 5 days during the early signs of an upper respiratory tract illness, for preventing the development of lower respiratory tract symptoms. APRIL is a 78 week study, but participation will end earlier if the child requires a fourth course of APRIL treatment or develops significant lower respiratory tract symptoms. Only those children who develop significant lower respiratory tract symptoms during APRIL will enter the OCELOT portion of the study, which will compare oral corticosteroid to placebo for treating lower respiratory tract symptoms as measured by the Pediatric Respiratory Assessment Measure (PRAM). OCELOT participation will be complete after 14 days. Children may not reenter APRIL after completing OCELOT.


Recruitment information / eligibility

Status Completed
Enrollment 607
Est. completion date January 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender Both
Age group 12 Months to 71 Months
Eligibility Inclusion Criteria:

- 12-71 months of age.

- Recurrent significant wheezing in the past year (any of the following):

- >3 episodes, =1 of which was clinically significant*; OR

- >2 clinically significant* episodes; OR

- >4 months of daily controller therapy AND >1 clinically significant* episode.

- * Clinically significant episode: requiring any of the following: (1) systemic corticosteroids (oral or injectable), (2) unscheduled physician office visit, (3) ED visit, (4) urgent care visit, or (5) hospitalization.

- Up to date with immunizations, including varicella (unless the subject has already had clinical varicella). If the subject needs varicella vaccine, this will be arranged with the primary care physician and must be received prior to randomization.

- Willingness to provide informed consent by the child's parent or guardian.

Exclusion Criteria:

Participants who meet any of the following criteria are NOT eligible for enrollment, but may be re-enrolled if these exclusion criteria are resolved:

- >4 courses of systemic corticosteroids in past 12 months.

- More than 1 hospitalization for wheezing illnesses within the preceding 12 months.

- Use of long-term controller medications for asthma, including inhaled corticosteroids, leukotriene modifiers, cromolyn/nedocromil, or theophylline for more than 8 months (cumulative use) in the past 12 months.

- Current use of higher than step 2 NAEPP asthma guideline therapy (e.g. medium-high dose ICS alone or combination therapy of low-medium-high dose ICS + LABA, montelukast, theophylline or cromolyn). NOTE: children who have evidence of well-controlled symptoms immediately preceding study entry while receiving Step 2 controller therapy (presence of self-reported symptoms on average no more than 2 times per week and less than 2 nights per month of nocturnal awakenings, requiring albuterol, during the 4 weeks preceding visit 1) may be enrolled and will have their controller therapy discontinued upon study entry.

- Use of OCS in the past 2 weeks.

- Daily symptoms or >2 nocturnal awakenings, requiring albuterol, on average in the last 2 weeks.

- Use of antibiotics in the past month.

- Current treatment with antibiotics for diagnosed sinus disease.

- Participation presently or in the past month in another investigational drug trial.

- Evidence that the family may be unreliable or nonadherent, or may move from the clinical center area before trial completion.

- Contraindication of use of systemic corticosteroids or azithromycin.

- Clinically relevant gastroesophageal reflux.

- Concurrent medical conditions other than asthma that are likely to require oral or injectable corticosteroids during the study.

- If receiving allergy shots, change in dose within the past 3 months.

Participants who meet any of the following criteria are NOT eligible for enrollment, and may not be re-enrolled:

- Gestation less than late preterm as defined as birth before 34 weeks gestational age.

- Presence of lung disease other than asthma, such as cystic fibrosis and BPD. Evaluation during the screening process will assure that an adequate evaluation of other lung diseases has been performed.

- Presence of other significant medical illnesses (cardiac, liver, gastrointestinal, endocrine) that would place the study subject at increased risk of participating in the study.

- Immunodeficiency disorders.

- History of respiratory failure requiring mechanical ventilation.

- History of hypoxic seizure.

- History of significant adverse reaction to any study medication ingredient.

- The child has significant developmental delay/failure to thrive, defined as crossing of two major percentile lines during the last year for age and gender. If a child plots less than the 10th percentile for age and gender, a growth chart for the previous year will be obtained from the child's primary care provider.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Azithromycin
Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
Prednisolone
Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
Other:
Placebo Azithromycin
Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
Drug:
Placebo Prednisolone
Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day

Locations

Country Name City State
United States University of New Mexico Albuquerque New Mexico
United States Emory University Atlanta Georgia
United States Children's Hospital Boston Boston Massachusetts
United States University of Virginia Health System Charlottesville Virginia
United States Children's Memorial Hospital Chicago Illinois
United States Rush University Medical Center Chicago Illinois
United States University of Chicago Chicago Illinois
United States University Hospitals Case Medical Center Cleveland Ohio
United States National Jewish Health Denver Colorado
United States University of Wisconsin Madison Wisconsin
United States Center for Urban Population Health Milwaukee Wisconsin
United States Children's Hospital & Research Center Oakland Oakland California
United States Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania
United States UCSF Benioff Children's Hospital San Francisco California
United States St. Louis Children's Hospital St. Louis Missouri
United States University of Arizona College of Medicine Tucson Arizona

Sponsors (2)

Lead Sponsor Collaborator
Milton S. Hershey Medical Center National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary APRIL: progression to clinically significant lower respiratory tract symptoms 14 days after initiation of APRIL therapy No
Primary OCELOT: Pediatric Respiratory Assessment Measure 36-72 hours after initiation of OCELOT therapy No
Secondary asthma related symptoms 14 days after initiation of therapy No
Secondary absence from school, daycare, and/or parental work 14 days after initiation of therapy No
Secondary urgent care visits, ED visits and hospitalizations 14 days after initiation of therapy No
Secondary drug related side effects 14 days after initiation of therapy No
See also
  Status Clinical Trial Phase
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device